CRO and Vendor Oversight in Clinical Trials

Most clinical trials are partially or fully outsourced. ICH E6(R3), in force from July 2025 under the EMA and expected to be adopted by the U.S. FDA, raises the governance standard for sponsor oversight of contract research organisations (CROs) and other vendors. Sponsors retain full accountability for trial quality, regardless of what they outsource.

Image

Why Vendor Oversight Is a Compliance Risk

The most common finding in U.S. Food and Drug Administration (FDA) inspection reports for clinical trials is inadequate sponsor oversight of investigators and vendors.

International Council for Harmonisation Compliance standards (ICH E6[R3]) address this directly by requiring sponsors to document the rationale for outsourcing decisions, maintain oversight of delegated activities, and ensure that vendor personnel are trained and qualified to the same Good Clinical Practice (GCP) standard as direct sponsor staff.

This is not a new requirement. What E6(R3) changes is the explicitness of the expectation: Oversight must be proportionate to the risk that each outsourced activity presents to participant safety and data integrity.

Generic audit schedules applied uniformly to all vendors no longer satisfy the spirit of the guidance.

Image

What ICH E6(R3) Requires from Sponsor-CRO Relationships

ICH E6(R3) sets out specific expectations for how sponsors structure and manage vendor relationships:

• Written agreements. Contracts must clearly document which GCP responsibilities are transferred to the CRO and which remain with the sponsor. Ambiguity in responsibility allocation is a direct compliance risk.
• Risk-proportionate oversight. Sponsors must apply greater oversight intensity to vendor activities that carry higher risk to participant safety or primary endpoint data. Low-risk administrative activities receive proportionately less oversight.
• Training and qualification verification. Sponsors must confirm that all vendor personnel, including remote staff in decentralised trials, are appropriately trained. This applies to local healthcare providers and third-party site staff as well as CRO clinical research associates.
• Quality escalation protocols. E6(R3) requires sponsors to have defined processes for escalating quality issues identified at vendor sites, including thresholds for sponsor intervention and audit trigger criteria.

From Vendor Management to Strategic Partnership

The sponsor-CRO relationship has historically been transactional, defined by scope-of-work contracts, milestone payments, and periodic performance reviews. As trial complexity increases and outsourcing expands, this model generates friction at critical decision points.

Sponsors with more integrated CRO partnerships consistently outperform on key trial metrics.

Integrated governance structures, including joint steering committees, shared risk registers, and aligned key performance indicators (KPIs), reduce decision latency when issues arise mid-trial.

For CROs, the shift toward strategic partnership also changes their risk exposure.

CROs that operate under risk-share arrangements, where compensation is tied to trial performance metrics rather than activity completion, have a direct financial incentive to escalate emerging issues rather than managing them locally.

Image

Key Performance Metrics for Vendor Oversight

Effective vendor oversight requires measurable indicators, reviewed at defined intervals:

• Protocol deviation rates by site and vendor, stratified by severity.
• Data entry timeliness and query resolution rates as indicators of site data management quality.
• Serious adverse event (SAE) reporting timelines against contractual and regulatory requirements.
• Enrolment rate variance from projections, by site and geography.
• Audit finding trends, distinguishing isolated incidents from systemic patterns requiring intervention.

Centralised monitoring platforms, supported by E6(R3)'s technology-neutral framework, allow sponsors to track these metrics in real time across global site networks, enabling earlier detection of vendor performance issues.

What Sponsors Must Implement Now for Compliant Clinical Studies

Three immediate priorities follow from E6(R3) and the broader shift toward strategic outsourcing governance:

• Audit and update vendor contracts. Existing agreements should be reviewed against E6(R3)'s requirements for responsibility allocation, training verification, and quality escalation. Gaps must be addressed before the next inspection cycle.
• Build risk-proportionate oversight plans. For each outsourced activity, document the risk rationale and the corresponding oversight method. This documentation is the primary evidence that a sponsor has met E6(R3)'s proportionality requirement.
• Establish joint governance structures. Joint steering committees with CROs, shared risk registers, and aligned KPIs reduce decision latency and create the accountability structure that E6(R3) expects sponsors to maintain.

Pharmatica tracks the operationalisation of ICH E6(R3) across sponsor and CRO organisations globally, providing clinical operations and regulatory leadership with the governance intelligence they need to build compliant, high-performing outsourcing relationships.